Thursday, Cardinal Health Inc (NYSE:CAH). announced the results of its Annual Meeting of Shareholders held on November 6, 2024, where shareholders voted on several key proposals, including the election of the company's board of directors and executive compensation.
The company, headquartered in Dublin, Ohio, reported that all 10 nominees were elected to its Board of Directors. They will serve until the next annual meeting in 2025 or until their successors are duly elected and qualified. The elected board members garnered significant support, with the majority receiving well over 190 million votes in favor.
Additionally, shareholders approved the compensation of Cardinal Health's named executive officers, commonly referred to as the "say-on-pay" vote. This non-binding advisory vote reflects shareholder support for the company's executive compensation policies and practices.
The appointment of Ernst & Young LLP as the company's independent auditor for the fiscal year ending June 30, 2025, was ratified with an overwhelming majority of votes in favor, totaling over 202 million.
However, a shareholder proposal that sought to prohibit the re-nomination of any director who fails to receive a majority vote was not approved. This proposal received significantly less support, with approximately 37 million votes in favor compared to over 155 million votes against.
These voting results are based on a press release statement and indicate the shareholders' confidence in the company's governance and executive leadership. Cardinal Health, a distributor of pharmaceuticals and medical products, trades under the ticker symbol NYSE:CAH.
In other recent news, Cardinal Health Inc. reported a robust beginning to fiscal year 2025, with raised earnings per share (EPS) and adjusted free cash flow expectations. Despite a 4% decrease in total revenue, the company's operational performance, especially in the Pharmaceutical (TADAWUL:2070) and Specialty Solutions segment, led to an increased EPS guidance to $7.75-$7.90 and an improved cash flow forecast.
Cardinal Health also announced plans to acquire Integrated Oncology Network for $1.1 billion.
The company expects full-year COVID-19 vaccine revenue growth to remain at 18%-20%, while Theranostics products in oncology and at-home solutions saw over 20% revenue growth. However, the GMPD segment experienced profit declines and faced challenges from recent hurricanes.
Despite these hurdles, Cardinal Health remains optimistic about its long-term profit goals and growth strategies. The acquisition of Integrated Oncology Network is expected to close by year's end, and the company continues to focus on specialty and at-home solutions while exploring further M&A opportunities.
InvestingPro Insights
Cardinal Health's recent shareholder meeting results reflect strong investor confidence, which aligns with several positive indicators from InvestingPro data. The company's market capitalization stands at $28.65 billion, underscoring its significant presence in the Healthcare Providers & Services industry.
InvestingPro Tips highlight Cardinal Health's commitment to shareholder value. The company has raised its dividend for 36 consecutive years and has maintained dividend payments for 42 years, demonstrating a strong track record of returning value to shareholders. This consistent dividend policy likely contributed to the shareholders' approval of executive compensation in the recent meeting.
Furthermore, Cardinal Health's financial health appears robust. The company's revenue for the last twelve months reached $224.45 billion, with a revenue growth of 6.87%. This growth, coupled with the expectation that net income will increase this year, suggests a positive outlook that may have influenced shareholders' decisions during the annual meeting.
It's worth noting that Cardinal Health is trading near its 52-week high, with a strong return of 16.45% over the last three months. This performance could be indicative of market confidence in the company's strategy and leadership, which was reaffirmed by the re-election of all board nominees.
For investors seeking more comprehensive analysis, InvestingPro offers 16 additional tips for Cardinal Health, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.